Bispecific Antibodies in Cancer Immunotherapy: Mechanisms, Challenges, and Emerging Therapeutic Strategies
Genomics, Proteomics & Bioinformatics · 31.07.2026
DOI: 10.1093/gpbjnl/qzag075 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genomics, Proteomics & Bioinformatics, online erschienen am 31.07.2026. Verfasst von Yao Wu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Public Center of Experimental Technology, School of Basic Medical Sciences, Southwest Medical University, Luzhou 646000, China. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Bispecific antibodies (BsAbs) have emerged as a promising therapeutic strategy in cancer immunotherapy, enabling simultaneous targeting of two distinct antigens to redirect immune effector cells, block compensatory pathways, and modulate the tumor immune microenvironment (TIME). Hundreds of BsAbs are currently in clinical trials, among which immune cell engagers (ICEs) demonstrate substantial therapeutic potential by bridging tumor cells and effector cells to enhance cytotoxic activity. However, the clinical translation of BsAbs is hampered by heterogeneous therapeutic responses, immune-related adverse events (irAEs), drug resistance, and inherent immunogenicity. In this review, we systematically dissect the applications of BsAbs in tumor immunotherapy, focusing on rational target combinations, underlying immunological mechanisms, and clinical therapeutic potential, while critically evaluating the advantages and limitations of representative BsAb modalities. We aim to address a key unresolved question: why some BsAb regimens achieve durable clinical efficacy (e.g., blinatumomab in hematological malignancies), whereas others show limited activity in solid tumors (e.g., vanucizumab). Through comparative mechanistic analysis, we clarify the critical trade-offs among therapeutic efficacy, systemic toxicity, and immunosuppressive barriers within the tumor microenvironment. To mitigate these translational bottlenecks, we summarize cutting-edge engineering approaches–including trispecific antibodies, prodrug-conjugated BsAbs, and proteolysis-targeting chimeras (PROTACs) — that optimize the balance between anti-tumor potency and off-target toxicity. This review provides a conceptual framework for advancing the translational development of BsAbs and guiding the rational design of next-generation precision cancer immunotherapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Public Center of Experimental Technology, School of Basic Medical Sciences, Southwest Medical University, Luzhou 646000, China.
- School of Stomatology, Southwest Medical University, Luzhou 646000, China.
- Institute of Nuclear Medicine, Southwest Medical University, Luzhou 646000, China.
ORCID-Profile: Yao Wu, Mingjie Liao, Han Chen, Yingchun Ye, Xiyuan Guo, Lin Li, Qin Liu, Xiaomei Xu, Siji Nian, Qing Yuan
Zitieren
APA
Wu, Y., Liao, M., Chen, H., Ye, Y., Guo, X., Li, L., Liu, Q., Xu, X., Nian, S., & Yuan, Q. (2026). Bispecific Antibodies in Cancer Immunotherapy: Mechanisms, Challenges, and Emerging Therapeutic Strategies. Genomics, Proteomics & Bioinformatics. https://doi.org/10.1093/gpbjnl/qzag075
Vancouver
Wu Y, Liao M, Chen H, Ye Y, Guo X, Li L, et al. Bispecific Antibodies in Cancer Immunotherapy: Mechanisms, Challenges, and Emerging Therapeutic Strategies. Genomics, Proteomics & Bioinformatics. 2026. doi:10.1093/gpbjnl/qzag075
BibTeX
@article{Wu2026,
author = {Wu, Yao and Liao, Mingjie and Chen, Han and Ye, Yingchun and Guo, Xiyuan and Li, Lin and Liu, Qin and Xu, Xiaomei and Nian, Siji and Yuan, Qing},
title = {Bispecific Antibodies in Cancer Immunotherapy: Mechanisms, Challenges, and Emerging Therapeutic Strategies},
journal = {Genomics, Proteomics & Bioinformatics},
year = {2026},
doi = {10.1093/gpbjnl/qzag075}
}
EUVIMED